Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With <i>RAS</i> Wild-type, Left-Sided Metastatic Colorectal CancerJun Watanabe, Takayuki Yoshino, Kei Muro et al.|JAMA|2023Cited by 255
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trialKanwal Raghav, Takayuki Yoshino, Marc Peeters et al.|The Lancet Oncology|2024Cited by 124
Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancerKohei Shitara, Takayuki Yoshino, Kei Muro et al.|Nature Medicine|2024Cited by 108
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.Kanwal Raghav, Takayuki Yoshino, Salvatore Siena et al.|Journal of Clinical Oncology|2023Cited by 77